Insights learned from L457(3.43)R, an activating mutant of the human lutropin receptor

Molecular and Cellular Endocrinology

Volumn 260-262, Issue , 2007, Pages 287-293

  Latronico, Ana Claudia ^a   Segaloff, Deborah L ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Constitutive activation; Constitutively active mutant; G protein coupled receptor (GPCR); Lutropin receptor (LH receptor)

Indexed keywords

AMINOTRANSFERASE; ANASTROZOLE; ANTIANDROGEN; ARGININE; CYCLIC AMP; CYPROTERONE ACETATE; FINASTERIDE; G PROTEIN COUPLED RECEPTOR; GONADOTROPIN; KETOCONAZOLE; LUTEINIZING HORMONE RECEPTOR; MUTANT PROTEIN; PHOSPHODIESTERASE;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CYTOPLASM; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; MALE TYPE ALOPECIA; MUTAGENESIS; MUTATIONAL ANALYSIS; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; WILD TYPE;

ARGININE; CYCLIC AMP; HUMANS; LEUCINE; MUTANT PROTEINS; PUBERTY, PRECOCIOUS; RECEPTORS, LH;

EID: 33751200969     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2005.11.053     Document Type: Review

References (25)

1. Angelova K., Fanelli F., and Puett D. A model for constitutive lutropin receptor activation based on molecular simulation and engineered mutations in transmembrane helices 6 and 7. J. Biol. Chem. 277 (2002) 32202-32213
2. Ascoli M., Fanelli F., and Segaloff D.L. The lutropin/choriogonadotropin receptor: a 2002 perspective. Endocr. Rev. 23 (2002) 141-174
3. Ballesteros J.A., and Weinstein H. Integrated methods for the construction of three-dimensional models of structure-funcion relations in G protein-coupled receptors. Methods Neurosci. 25 (1995) 366-428
4. Bertelloni S., Baroncelli G.I., Lala R., Cappa M., Matarazzo P., De Sanctis C., and Saggese G. Long-term outcome of male-limited gonadotropin-independent precocious puberty. Horm. Res. 48 (1997) 235-239
5. Evans B.A.J., Bowen D.J., Smith P.J., Clayton P.E., and Gregory J.W. A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype. J. Med. Genet. 33 (1996) 143-147
6. Fanelli F. Theoretical study on mutation-induced activation of the luteinizing hormone receptor. J. Mol. Biol. 296 (2000) 1333-1351
7. Fanelli F., Verhoef-Post M., Timmerman M., Zeilemaker A., Martens J.W., and Themmen A.P. Insight into mutation-induced activation of the luteinizing hormone receptor: molecular simulations predict the functional behavior of engineered mutants at M398. Mol. Endocrinol. 18 (2004) 1499-1508
8. Kenakin T. Inverse, protein, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15 (2001) 598-611
9. Kenakin T. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1 (2002) 103-110
10. Latronico A., and Segaloff D. Naturally occurring mutations of the luteinizing hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors. Am. J. Hum. Genet. 65 (1999) 949-958
11. Latronico A.C., Abell A.N., Arnhold I.J.P., Liu X., Lins T.S.S., Brito V.N., Billerbeck A.E., Segaloff D.L., and Mendonca B.B. A unique constitutively activating mutation in the third transmembrane helix of the luteinizing hormone receptor causes sporadic male gonadotropin independent precocious puberty. J. Clin. Endocrinol. Metab. 83 (1998) 2435-2440
12. Latronico A.C., Lins T.S., Brito V.N., Arnhold I.J., and Mendonca B.B. The effect of distinct activating mutations of the luteinizing hormone receptor gene on the pituitary-gonadal axis in both sexes. Clin. Endocrinol. 53 (2000) 609-613
13. Laue L., Jones J., Barnes K.M., and Cutler Jr. G.B. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J. Clin. Endocrinol. Metab. 76 (1993) 151-155
14. Lin Z., Shenker A., and Pearlstein R. A model of the lutropin/choriogonadotropin receptor: insights into the structural and functional effects of constitutively activating mutations. Prot. Eng. 10 (1997) 501-510
15. Mirzadegan T., Benko G., Filipek S., and Palczewski K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42 (2003) 2759-2767
16. Muller J., Gondos B., Kosugi S., Mori T., and Shenker A. Severe testotoxicosis phenotype associated with Asp578 → Tyr mutation of the lutrophin/choriogonadotrophin receptor gene. J. Med. Genet. 35 (1998) 340-341
17. Rosenthal I.M., Refetoff S., Rich B., Barnes R.B., Sunthornthepvarakul T., Parma J., and Rosenfield R.L. Response to challenge with gonadotropin-releasing hormone agonist in a mother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor-a clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 3802-3806
18. 2-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
19. Shenker A., Laue L., Kosugi S., Merendino Jr. J.J., Minegishi T., and Cutler Jr. G.B. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365 (1993) 652-654
20. Shinozaki H., Butnev V., Tao Y.X., Ang K.L., Conti M., and Segaloff D.L. Desensitization of Gs-coupled receptor signaling by constitutively active mutants of the human lutropin/choriogonadotropin receptor. J. Clin. Endocrinol. Metab. 88 (2003) 1194-1204
21. Shinozaki H., Fanelli F., Liu X., Jaquette J., Nakamura K., and Segaloff D.L. Pleiotropic effects of substitutions of a highly conserved leucine in transmembrane helix III of the human lutropin/choriogonadotropin receptor with respect to constitutive activation and hormone responsiveness. Mol. Endocrinol. 15 (2001) 972-984
22. Soriano-Guillen L., Lahlou N., Chauvet G., Roger M., Chaussain J.L., and Carel J.C. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J. Clin. Endocrinol. Metab. 90 (2005) 147-151
23. Tao Y.-X., Mizrachi D., and Segaloff D.L. Chimeras of the rat and human FSH receptors (FSHRs) identify residues that permit or suppress transmembrane 6 mutation-induced constitutive activation of the FSHR via rearrangements of hydrophobic interactions between helices 6 and 7. Mol. Endocrinol. 16 (2002) 1881-1892
24. Themmen A.P.N., and Huhtaniemi I.T. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr. Rev. 21 (2000) 551-583
25. Zhang M., Mizrachi D., Fanelli F., and Segaloff D.L. The formation of a salt bridge between helices 3 and 6 is responsible for the constitutive activity and lack of hormone responsiveness of the naturally occurring L457R mutation of the human lutropin receptor. J. Biol. Chem. 280 (2005) 26169-26176